Erbi Biosystems joins cell manufacturing research initiative to develop the next generation of cell therapies April 26, 2022, Boston, MA and Atlanta, GA: Erbi Biosystems has joined the National Science…
KTH Royal Institute of Technology, Karolinska University Hospital and Lund University partner with Erbi Biosystems to develop intensified bioprocesses, covering biologics, gene and cell therapies. BOSTON and STOCKHOLM, March 23,…
Manufacturers of the only commercially available mL-scale bioreactor with fully automated True Perfusion™ capability, has secured additional funding to expand its solutions for cell therapy development and manufacturing CAMBRIDGE, Mass., Jan.…
This webcast features: Kevin Lee, Co-Founder, Principal Scientist, Erbi Biosystems The priority of speed to market is often at odds with issues around development resources, facility space, and infrastructure for both…
WOBURN, Mass., Oct. 30, 2020 -- Erbi Biosystems, a transformative microfluidic bioprocess instrumentation company based on technology developed at MIT, announced today the closing of a finance round which brings the…
Scaled down models are becoming increasingly important to cell line and media development, as well as overall process optimization. These models provide the opportunity to run multiple experiments in parallel…